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Background: Spinal and bulbar muscular atrophy (SBMA) or Kennedy disease [OMIM:
313200] is a rare X-linked neuromuscular disease. Patients commonly present with
muscle cramps, tremors, leg weakness, dysarthria and dysphagia.
Methods: We deeply phenotyped and evaluated the possible extent of affected systems
in all patients with SBMA in Latvia (n = 5). In addition, neurophysiological studies and
blood analyses were used to perform a molecular diagnosis and evaluate biochemical
values. We analyzed neurofilament light (NfL) as a possible biomarker.
Results: Neurological examination revealed typical SBMA clinical manifestations; all
patients had small or large nerve fiber neuropathy. Three of five patients had increased
neurofilament light levels.
Conclusion: The study confirms the systemic involvement in patients suffering from
SBMA. Increased NfL concentration was associated with either peripheral neuropathy or
decreased body mass index. The complex phenotype of the disease should be kept in
mind, as it could help to diagnose patients with SBMA.
Keywords: Kennedy disease, spinal and bulbar muscular atrophy, phenotype, clinical features, biomarker,
neurofilament
INTRODUCTION
Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy disease, is a rare X-linked
neuromuscular disease (1). It is caused by a CAG repeat expansion resulting in >35 CAGs in
the first exon of the androgen receptor (AR) gene (polyglutamine disease) (2). The mutant AR
aggregates in the nucleus of a cell and results in direct toxicity to the cell (mostly, lower motor
neurons and myofibrils), which clinically results in slowly progressive adult-onset lower motor
neuron damage and primary myopathy early in the course of the disease (3, 4). Interestingly,
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myopathic changes in transgenic mouse models of SBMA
were observed prior to any motor neuron degeneration,
illustrating motor neuron involvement only in the later
stages of SBMA (5–7). Additionally, the polyglutamine
expansion causes loss of receptor activity and results in
androgen insensitivity.
The reported prevalence of SBMA is highly variable.
Recent data in Italy indicated a SBMA prevalence of
2.58/100,000 in the male population (8), while it is higher
in regions with a suggested founder effect, such as in the
Vasa region of Finland where the estimated prevalence is
15/100,000 male inhabitants (8, 9). The exact prevalence,
however, is still unknown, because SBMA is thought to be
underdiagnosed (10).
Patients with SBMA commonly present with slowly
progressive muscle weakness as the main clinical feature, which
typically starts in the lower limbs proximally and progresses
during the course of the disease to also involve the bulbar
and distal limb muscle groups (2, 3). Other symptoms such
as cramps, myalgia and postural hand tremors are frequently
reported long before the onset of muscle weakness. Lower motor
neuron signs are persistent, including diminished or absent deep
tendon reflexes and fasciculations in the limb muscles, tongue,
and chin, as well as muscle atrophy (2–4, 11). The onset of the
neurological symptoms is variable and ranges from 20 to 60 years,
but SBMA typically manifests during the fourth or fifth decade
of life. The CAG repeat size inversely correlates with the disease
onset, with longer repeats associated with earlier onset but not
with disease progression or severity (4). Additionally, androgen
insensitivity leads to gynecomastia, reduced fertility, and erectile
dysfunction (2, 12).
Recent studies and separate case series have found that
SBMA might also affect other parts of the nervous system
and can be associated with metabolic alterations. Additional
neurological features include peripheral neuropathies and
dysfunction of the autonomic system, while metabolic
alterations include dysregulation of both glucose homeostasis
(glucose intolerance and diabetes) and lipid metabolism
(dyslipidaemia). These findings suggest that SBMA is a systemic
disorder (2, 12).
Determining disease progression in clinical trials with limited
time frame for a slowly progressing disease could be challenging.
Several possible neuronal and muscle biomarkers of SBMA
severity have been previously studied. Creatinine, instead of
creatinine kinase, demonstrates capabilities as a biomarker by
reflecting SBMA severity viamusclemass decrease (13, 14). Blood
concentrations of the axonal damage marker neurofilament light
(NfL) has been reported to be unchanged in patients with
SBMA (14).
The involvement of various systems has been previously
assessed separately, analyzing one or several systemic
manifestations mostly in a limited number of patients with
SBMA. Therefore, in this study, we deeply phenotyped
all patients with SBMA in Latvia to evaluate the possible
simultaneous extent of the involved systems previously reported




All patients diagnosed with spinal and bulbar muscular atrophy
in Latvia (five unrelated Caucasian male patients) were included
in this study. For the comparison of plasma NfL levels, 21 healthy
male controls without known neurological disease or neurologic
symptoms were enrolled in this study as a control group.
Clinical and Laboratory Examination
Clinical characteristics, including neurological status testing, 6-
min walking testing, and hand grip testing, were evaluated by a
certified neurologist at the time of enrolment into the study.
All patients underwent neurophysiological studies, including
nerve conduction study (NCS), needle electromyography (EMG),
and quantitative sensory testing (QST). For analysis of autonomic
nervous system (ANS) function, heart rate variability (ANS
Analysis Professional) and sympathetic skin response testing
were performed. 2 days before the ANS tests, the patients stopped
medication(s) that could influence the results.
Blood samples were used for investigating the following
biochemical and hormonal profiles: creatinine, creatine
phosphokinase, lipidogram, thyroid hormones (thyroid
stimulating hormone and free thyroxine), testosterone, and
glycated hemoglobin.
The NfL concentration in plasma was determined using the
single molecule array (Simoa) NfL assay (Quanterix, Billerica,
MA). For a quality control (QC) sample with a concentration of
15.8 pg/mL, repeatability was 5.2% and intermediate precision
was 5.2%. For a QC sample with a concentration of 50 pg/mL,
repeatability was 2.7% and intermediate precision was 3.2%.
The lower limit of quantification was 1.9 pg/mL. The samples
were analyzed by board-certified laboratory technicians who
were blinded to the clinical data. The levels with controls were
compared using Mann-Whitney U-test.
Molecular Analysis
The CAG repeat analysis in the AR gene was performed as
previously described (15). All analyses were performed using
capillary electrophoresis, and the results were confirmed by
Sanger sequencing for two patients with the shortest CAG
repeats using the BigDye Terminator Kit v.3.1 (Thermo Fisher
Scientific, USA), according to adapted manufacturer’s protocol.
The number of CAG repeats for longer alleles were calculated
based on fragment size.
Ethics
The study was approved by the Central Medical Ethics
Committee of the Republic of Latvia (Nr.3/18-03-21). All
individuals signed an informed consent form and allowed
anonymised publication of their clinical information and photos.
RESULTS
The study included all patients with SBMA in Latvia (n = 5)
that were 34–68 years old. Patient characteristics are shown in
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Table 1. The CAG repeat numbers were variable (range 47–
54). All patients had no positive family history for SBMA or
other neuromuscular diseases. Two of the patients also had
autoimmune thyroiditis, and one of the patients had primary
arterial hypertension. No other comorbidities were reported
during the study. For two of the patients, SBMA manifested
during their thirties, although the earliest onset was at the age of
six based on the patient’s anamnesis data (the first complains was
inability to perform the same sports activities as other children).
Almost all patients indicated their initial symptoms as general
fatigue and muscle cramps.
Clinical and neurological examination revealed limb weakness
in all patients. Weakness was more prominent proximally in
the lower extremities and asymmetric between the left and right
side for almost all patients (Table 2). Patient 4, with the earliest
manifestation of the disease, also had the most severe weakness
in the extremities. Facial muscle weakness, diffuse fasciculations,
absent tendon reflexes, and tongue atrophy were present in all
subjects (Figure 1). Two patients had dysphagia and two had
dysarthria. During examination, all patients had prominent hand
tremor, and Patient 3 also presented with bilateral myotonia
in the palms. Sensory assessment revealed glove and stocking-
like sensory impairment as hyperesthesia for Patients 1 and 3
and hypoesthesia for Patient 5. Gynecomastia was observed in
four out of five patients. Patients without gynecomastia had
low body mass index (BMI), 18.7 kg/m2. All patients noted
sweating disturbances, but due to the small sample size and
subjectivity of the complaints, it was questionable whether these
TABLE 1 | Patient characteristics.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age at examination / age
at onset* (years)
38/33 46/36 35/14 34/6 68/45
CAG repeats 50 48 54 47 53
Family history Negative Negative Negative Negative Negative







Body Mass Index (kg/m²) 30.4 25.4 22.5 18.7 24.6
*Self-reported by patient.
TABLE 2 | Clinical features.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5









































Dysphagia - + - - +
Dysarthria - - - + +
Dysphonia - - - - +
Facial muscle weakness
(Figure 1)
+ + + + +
Tongue atrophy
(Figure 1)
+ + + + +
Tendon reflexes Absent Absent Absent Absent Absent
Fasciculations Diffuse Diffuse Diffuse Diffuse Diffuse
Muscle cramps Diffuse Diffuse
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FIGURE 1 | Facial muscle weakness and tongue atrophy.
TABLE 3 | Patient functional characteristics.
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
6-min walking distance in meters
[norm value (16)]
540 (580) 510 (580) 500 (580) 345 (580) 195 (580)
Hand grip test right/left in kg
[age specific norm (17)]




TABLE 4 | Neurophysiological findings.





Normal Normal Normal Severe motor, sensory
demyelinating axonal
polyneuropathy
Electromyography Neurogenic changes Neurogenic changes Neurogenic changes Neurogenic changes Neurogenic changes
Quantitative sensory
testing
A delta type fiber
dysfunction
C type fiber dysfunction C type fiber dysfunction A delta and C type fiber
dysfunction
A delta and C type fiber
dysfunction













Increased latency Increased latency,
decreased amplitude
Normal
complaints could be associated with BMI. All patients had
decreased 6-min walking distances (Table 3) (16). All patients
had clearly decreased hand grip testing results with poor scores
for both hands.
In all patients, needle EMG showed clear signs of neurogenic
changes in all examined muscles, with large polyphasic
motor unit potentials, fibrillation potentials, and fasciculations
(Table 4). Motor and sensory nerve conduction velocities and
compound muscle action potentials and sensory action potential
amplitudes were abnormal for two out of five patients. Patient
1 had signs of sensory demyelinating polyneuropathy with
decreased sensory conduction velocities, and Patient 5 had
severe motor sensory demyelinating axonal polyneuropathy.
QST revealed abnormalities of tactile thresholds and mechanical
pain perception in all patients, which was isolated in C sensory
fiber types in two patients, A-δ fiber types in one patient and
abnormalities in both types of sensory fibers in two patients.
Evaluation of the ANS via heart rate variability (ANS Analysis
Professional) showed marked differences between patients.
Patients 1 and 5 had no abnormalities; however, three patients
had signs of ANS dysfunction. Patient 2 had signs of cardiac
autonomic neuropathy (tachycardia), Patient 3 had sympathetic
dysfunction, and Patient 4 had parasympathetic dysfunction.
Sympathetic skin response testing results indicated that three
out of five patients had peripheral sympathetic nervous system
dysfunction, with all of them (3/5) demonstrating increased
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latency, and Patients 2 and 4 also had decreased amplitude
during examination.
All patients had markedly elevated creatine phosphokinase
levels, with the highest result reaching 5,000 U/L. All patient
serum creatinine levels were within the normal range. To
determine possible metabolic dysfunction linked to the
pathogenesis of the disease, lipidogram, thyroid hormones,
testosterone, and glycated hemoglobin levels were analyzed
(Table 5). Two patients had increased testosterone levels,
indicating androgen resistance. All patients had dyslipidaemia.
Regarding thyroid function, two patients had autoimmune
thyroiditis according to antibody (anti-thyroid peroxidase)
and thyroid ultrasonography findings. Only Patient 3 had a
subclinical decrease in thyroid function with increased thyroid
stimulating hormone, despite demonstrating free thyroxine
levels within the normal range.
NfL concentration was the highest for Patient 5 (20.62 pg/mL),
followed by Patients 1 (10.56 pg/mL) and 4 (10.01 pg/mL).
Our NfL control group consisted of 21 male participants, with
a mean age of 27.3 ± 11.7 (range 5–55 years). There was no
difference in age between the patient and control groups (p >
0.05). The mean NfL chain concentration among control group
participants was 5.08 ± 1.76 pg/mL, ranging from 2.60 pg/mL to
8.80 pg/mL. Patient 5 had markedly increased NfL concentration
in comparison with our control group, while Patients 1 and 4
also had higher NfL concentrations (>2.5 SD) than the control
group. In total, SBMA patients group had higher NfL level than
controls (p < 0.01).
DISCUSSION
In the current study, we have performed deep phenotyping and
evaluation of possible biomarkers of all patients diagnosed with
spinal and bulbar muscular atrophy in Latvia to unravel the
extent of affected systems per patient, as well as to confirm that
SBMA is a multisystemic condition.
Patients reported in this study exhibited typical features of
SBMA with asymmetric atrophy and weakness of the proximal
limb and bulbar muscles, as well as hand tremor consistent
with lower motor neuron and skeletal muscle damage. Clinical,
electrophysiological, and laboratory phenotyping of the patients
allowed us to identify other symptoms and signs of SBMA that
are rarely described or investigated. CAG repeat numbers in
our SBMA group were variable (range 47–54). Although it has
been reported that longer CAG repeats are associated with earlier
onset of disease, our data did not show this association. However,
our study group was very small. One reason for this could
be that the onset of disease was reported by patients, while it
could have started earlier or later than stated from the point of
view of patients. CAG repeats are also associated with disease
severity, which could have influenced our results. Themean CAG
repeats in our group was 50.4, which was higher than previously
reported (4).
Subclinical sensory involvement is common in patients with
SBMA, affecting 70–100% of patients, even when motor nerve
conduction studies are within reference range (3, 18). In SBMA,
a typical feature is reduced sensory action potential amplitudes
with axon loss, although decreased nerve conduction velocity
and demyelination may also be present (19). In our study, all
patients had small nerve fiber damage and two patients also
had large nerve fiber damage detected in NCSs. Patient 1 had
sensory demyelinating neuropathy, and Patient 5 had severe
motor sensory demyelinating axonal polyneuropathy. There was
no other confirmed cause for the severely manifested peripheral
neuropathy. Sensory manifestations of SBMA in peripheral
neuropathy and damage to both large and small nerve fibers are
believed to be caused by the toxicity caused by accumulation of
the mutant AR in dorsal root ganglion neurons in combination
with metabolic alterations (18, 20, 21). Small-fiber involvement
in SBMA could explain the neuropathic pain reported in some
patients (22). Antonini et al. previously evaluated small nerve
fiber involvement in a cohort of six patients with SBMA and
were not able to find damage to small myelinated (A-δ) and
unmyelinated (C types) nerve fibers by analyzing nerve biopsies
of three patients with SBMA, although they found dysfunction
in pain pathways among all six patients with SBMA that were
TABLE 5 | Biochemical and hormonal profile.
Normal range Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Cholesterol (mmol/l) <5.0 4.04 4.74 5.19 4.83 4.72
Triglycerides (mmol/l) <1.7 2.71 1.12 1.48 0.98 2.36
High density lipoprotein -cholesterol (mmol/l) >1.0 1.12 1.24 1.07 1.31 1.27
Low density lipoprotein -cholesterol (mmol/l) <3.0 2.19 3.06 3.4 2.82 2.38
Creatinine (µmol/L) 76–90 49 45 52 54 47
Creatine phosphokinase (U/L) 20–200 1,500 5,000 4,500 1,300 1,080
Thyroid stimulating hormone (mU/L) 0.4–4.0 1.3 1.3 12.86 1.5 0.4
Free thyroxine (pmol/L) 10.3–24.5 16.4 14.9 14.05 14.3 10.18
Glycated Hemoglobin (%) 4.0–6.0 4.9 5.5 4.9 4.7 5.3
Total testosterone level (ng/mL) 3.30–8.05 4.80 5.66 10.53 8.60 7.64
Neurofilament light (pg/mL) <9.5* 10.56 4.37 5.20 10.01 20.62
*Based on our control group data.
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investigated by using laser evoked potentials (23). However,
another group was able to find the involvement of the small nerve
fibers in two patients with SBMA byQST and skin biopsy analysis
(20). Our data not only confirms the involvement of small nerve
fibers in the pathogenesis of SBMA but also suggest that it may
be a common feature among these patients.
The ANS is not considered to be affected during the
course of SBMA, as patients usually do not exhibit symptoms
suggesting ANS dysfunction. There is a study by Rocchi
et al. analyzing ANS dysfunction in patients with SBMA,
which analyzed five patients with SBMA without diabetes,
impaired glucose tolerance, or cardiovascular diseases with
five autonomic function tests (24). They observed subclinical
dysfunction in the sympathetic and parasympathetic systems
in four out of five patients (24). However, no patients
exhibited symptoms of dysautonomia. Another group observed
moderate autonomic skin denervation and reduced sweating
in two patients with SBMA by analyzing skin biopsies and
amount of sweating after pilocarpine stimulation (20). Our
study confirms the involvement of the ANS and extends the
knowledge of dysautonomic symptoms in patients with SBMA.
Three out of five patients had involvement of the sympathetic
or parasympathetic ANS, as shown by heart rate variability
and sympathetic skin response test. It should be noted that
two patients also demonstrated symptomatic ANS dysfunction.
Patient 2 had tachycardia, and Patient 3 had tachycardia with
increased sweating. Both patients were using beta-blockers to
treat the tachycardia. Presentation of burning neuropathic pain
in the distal extremities with dysautonomic symptoms, such as
decreased sweating and difficulties with ejaculation, was recently
reported in a patient with the highest number of CAG repeats
known (68 CAG repeats) and confirms the involvement of small
nerve fibers, as well as ANS, in the course of the disease (22).
Previously reported damage to neurons from the AR toxicity in
central neural autonomic regions (e.g., hypothalamus, nucleus
ambiguous, and spinal intermediolateral nucleus, as well as in
sympathetic ganglia) (21) could explain the involvement of the
ANS among patients with SBMA. Additionally, it was suggested
that ANS damage could also be caused by disruption of the small
nerve fibers (post-ganglionic unmyelinated fibers) of the ANS
(22). Altogether, our data, as well as previous data, show that the
ANS is also involved in SBMAbut is rarely symptomatic. We find
it peculiar that sensory polyneuropathy and ANS involvement
were mutually exclusive. Polyneuropathy was reported in two
patients, while ANS damage was reported in three patients.
These findings are in agreement with the hypothesis that damage
to different parts of the nervous system in SBMAmay have
different pathogeneses.
Lower urinary tract symptoms (LUTS) without benign
prostatic hyperplasia has been reported in up to 40% of the
patients (25). The cause of LUTS in these patients is unknown
and is hypothesized to be caused by androgen insensitivity.
Despite the fact that none of our patients with dysautonomia
reported LUTS, we hypothesize that at least some of the
patients had LUTS as a result of ANS involvement (which
was not recognized previously). It should be noted that LUTS
could be present among our patient population but was not
diagnosed, because it was not objectively evaluated using
specific tools (e.g., International Prostate Symptom Score) in
our patients.
Plasma NfL concentration is a known biomarker for various
nervous system disorders in the central, as well as peripheral,
nervous systems, reflecting axonal damage (26). A recent study
investigated NfL as a biomarker of SBMA severity and found
no difference in mean NfL levels between the SBMA patient
and control groups, although several outliers with increased
NfL levels were found (14). It should be noted that NfL
level measurement was performed using the same method as
in the previous study. In our study, three of five patients,
however, demonstrated increased NfL levels. Two of these
patients (Patients 1 and 5) had polyneuropathy confirmed by
NCSs. Previous studies have shown that demyelinating and
axonal forms of inherited neuropathies both have increased
levels of NfL (27). We speculate that the NfL level for these
two patients reflects peripheral nerve damage due to peripheral
polyneuropathy. Patient 5 had severe polyneuropathy, as well as
the highest NfL concentration. It has been reported that there
is an age-dependent NfL increase, which could suggest that
other factors were influencing the NfL level in Patient 5 (27).
Patient 4 had increased NfL levels despite having no detectable
polyneuropathy. Patient 4 had a BMI at the lower threshold
of normal values (18.7 kg/m²), which has been reported to
result in a NfL increase in patients with anorexia nervosa (28).
We hypothesize that increased NfL reflects the involvement of
additional systems (peripheral nervous system) or other factors
(age, BMI and other). The previous study by Lombardi et al.
(14), which did not find NfL level differences between patients
with SBMA and controls, did not describe whether patients with
SBMA had involvement of additional systems. Therefore, we
hypothesize that NfL can be used as a biomarker of peripheral
polyneuropathy in SBMA but requires validation in a larger
cohort with detailed evaluation of multisystemic involvement
and other influencing factors, possibly in patients with SBMA
from our geographic region.
All patients in our study had increased creatine
phosphokinase levels, indicating muscle damage, and normal
creatinine levels. Elevation of creatine phosphokinase in patients
with SBMA could reflect myopathic damage. Creatinine for
all our patient cohort was under reference range reflecting
possible muscle damage (29). Laboratory studies confirmed a
high prevalence of dyslipidaemia (reported in 4/5 patients) and
a low prevalence of diabetes (no patient in our study group), as
assessed by the glycated hemoglobin, which was similar to other
studies (2, 18, 30) although impaired glucose tolerance, which is
common, was not assessed. Endocrinopathies (thyroid disorders
or partial androgen insensitivity) is also common and affected
all our patients. The metabolic abnormalities are believed to be
caused by androgen insensitivity.
Heart muscle is usually spared despite the well-known
primary myopathic damage in SBMA and AR accumulation
that occurs in the cardiomyocyte nuclei (18, 31). Araki et al.
described the common occurrence of Brugada syndrome in
up 12% of patients with SBMA from Japan (31). Occurrence
of Brugada syndrome was also observed among Caucasian
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patients with SBMA, although at a much lower frequency (up
to 4%) (25). We were not able to find electrocardiographic
abnormalities (excluding tachycardia in Patients 2 and 3),
which was most probably due to the low frequency of
cardiac involvement.
The main limitation of this study is the small sample size.
However, we were able to analyse most of the symptoms reported
in patients with SBMA, as well as replicate and confirm previous
findings, to provide the information about the extent of affected
systems by deeply phenotyping five patients with SBMA. Other
features and symptoms reported in SBMA patients that were
not analyzed in our study were only a subclinical change in
brain metabolism, osteopenia, and non-alcoholic steatohepatitis
(18, 32, 33). Additionally, we were able to raise hypotheses
that should be validated in larger cohorts. Besides the limited
number of patients, another bias of our study is that our
patients are younger than those analyzed in other studies, and
the mean CAG repeat count was higher than in other studies.
Unfortunately, muscle, skin or nerve biopsy was not available for
further examination.
Our study confirms the systemic involvement in patients
suffering from SBMA and expands knowledge about some of the
features regarding ANS and small nerve fiber involvement, which
have been inconclusive in previous studies. Our data show that
small nerve fibers and the ANS are commonly affected in patients
with SBMA. In our study, NfL showed biomarker capabilities
with regard to the peripheral polyneuropathy in SBMA but
requires validation in a bigger well-phenotyped cohort, where
more factors influencing the NfL levels in patients are known.
The complex phenotype of SBMA should be kept in mind, as it
could help to identify and diagnose patients with SBMA, as well
as provide explanations for the non-typical symptoms patients
may have. In the age of therapy of genetic disorders, correct and
timely diagnosis could also help in providing timely treatment
for patients.
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